General
Preferred name
plicamycin
Synonyms
Mithramycin A ()
mithramycin ()
P&D ID
PD009220
CAS
97666-60-9
18378-89-7
Tags
available
drug
natural product
Approved by
FDA
First approval
1970
Drug indication
Ovarian cancer
Lung cancer
Testicular cancer
Hypercalcaemia
Solid tumour/cancer
Drug Status
approved
withdrawn
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Plicamycin (Mithramycin A) is a selective specificity protein 1 (Sp1) inhibitor. Plicamycin inhibits the growth of various cancers by decreasing Sp1 protein. Plicamycin inhibits GSTM2 promoter activity and protein expression[1][2].
DESCRIPTION We show one representation of mithramycin here. As a natural product there are alternate chemical structures due to the complex stereochemistry. Also known as plicamycin, the compound has been used clinically as an antineoplastic antibacterial (produced by Streptomyces plicatus). (GtoPdb)
Cell lines
15
Organisms
0
Compound Sets
11
Cayman Chemical Bioactives
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Nuisance compounds in cellular assays
Withdrawn 2.0
External IDs
34
Properties
(calculated by RDKit )
Molecular Weight
1084.47
Hydrogen Bond Acceptors
24
Hydrogen Bond Donors
11
Rotatable Bonds
15
Ring Count
8
Aromatic Ring Count
2
cLogP
-0.25
TPSA
358.2
Fraction CSP3
0.77
Chiral centers
25.0
Largest ring
6.0
QED
0.11
Structural alerts
1
Protein disruption
RNA polymerase inhibition
Nuisance compounds
Custom attributes
(extracted from source data)
ATC
L01DC02
Pathway
Anti-infection
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Target
antibiotic
Bacterial
DNA/RNA Synthesis
Glutathione S-transferase
Source data